ACM
ADAR1 Capital Management Portfolio holdings
AUM
$616M
This Quarter Return
+12.77%
1 Year Return
+26.77%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$616M
AUM Growth
+$616M
(+19%)
Cap. Flow
+$33.1M
Cap. Flow
% of AUM
5.37%
Top 10 Holdings %
Top 10 Hldgs %
49.49%
Holding
239
New
40
Increased
61
Reduced
56
Closed
33
Top Buys
| 1 |
Keros Therapeutics
KROS
|
$52.1M |
| 2 |
Prothena Corp
PRTA
|
$20.5M |
| 3 |
SPDR S&P 500 ETF Trust
SPY
|
$14M |
| 4 |
CytomX Therapeutics
CTMX
|
$6.89M |
| 5 |
ABVX
Abivax
ABVX
|
$6.59M |
Top Sells
| 1 |
RAPT Therapeutics
RAPT
|
$41.5M |
| 2 |
Roivant Sciences
ROIV
|
$17.4M |
| 3 |
SWTX
SpringWorks Therapeutics
SWTX
|
$8.63M |
| 4 |
Immunovant
IMVT
|
$6.94M |
| 5 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$6.34M |
Sector Composition
| 1 | Healthcare | 83.61% |
| 2 | Financials | 2.95% |
| 3 | Consumer Discretionary | 0% |
| 4 | Utilities | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
INZY
151
DELISTED
Inozyme Pharma
INZY
| $149K | 0.02% |
37,161
-50,638
| -58% | -$203K |
|
|
CLYM
152
Climb Bio, Inc. Common Stock
CLYM
$150M
| $148K | 0.02% |
119,320
| – | – |
|
153
Design Therapeutics
DSGN
$320M
| $143K | 0.02% |
+42,408
| New | +$143K |
|
154
UroGen Pharma
URGN
$893M
| $137K | 0.02% |
+10,000
| New | +$137K |
|
155
BiomX
PHGE
$14.6M
| $135K | 0.02% |
299,598
| – | – |
|
156
Clover Health Investments
CLOV
$1.37B
| $135K | 0.02% |
48,300
+20,000
| +71% | +$55.8K |
|
157
Avantor
AVTR
$8.96B
| $135K | 0.02% |
+10,000
| New | +$135K |
|
|
PCAPU
158
ProCap Acquisition Corp Unit
PCAPU
$212M
| $114K | 0.02% |
+10,680
| New | +$114K |
|
|
ALMS
159
Alumis Inc. Common Stock
ALMS
$484M
| $113K | 0.02% |
+37,788
| New | +$113K |
|
160
KalVista Pharmaceuticals
KALV
$711M
| $113K | 0.02% |
10,000
-25,743
| -72% | -$291K |
|
|
SLN
161
Silence Therapeutics
SLN
$230M
| $108K | 0.02% |
18,643
| – | – |
|
162
PMV Pharmaceuticals
PMVP
$74.7M
| $107K | 0.02% |
101,008
| – | – |
|
163
Terns Pharmaceuticals
TERN
$648M
| $106K | 0.02% |
+28,415
| New | +$106K |
|
164
enGene Holdings
ENGN
$243M
| $101K | 0.02% |
27,787
+3,988
| +17% | +$14.5K |
|
165
Achieve Life Sciences
ACHV
$151M
| $97.6K | 0.02% |
43,173
| – | – |
|
166
Organon & Co
OGN
$2.43B
| $96.8K | 0.01% |
10,000
| – | – |
|
167
Replimune Group
REPL
$455M
| $96.6K | 0.01% |
+10,400
| New | +$96.6K |
|
168
Pliant Therapeutics
PLRX
$98.2M
| $95.3K | 0.01% |
+82,189
| New | +$95.3K |
|
169
Syndax Pharmaceuticals
SNDX
$1.4B
| $93.7K | 0.01% |
+10,000
| New | +$93.7K |
|
170
ESSA Pharma
EPIX
$11.1M
| $85K | 0.01% |
+50,000
| New | +$85K |
|
171
Aurinia Pharmaceuticals
AUPH
$1.57B
| $84.7K | 0.01% |
+10,000
| New | +$84.7K |
|
172
Shattuck Labs
STTK
$47.8M
| $81.5K | 0.01% |
102,948
+792
| +0.8% | +$627 |
|
173
Relmada Therapeutics
RLMD
$46.5M
| $78K | 0.01% |
+130,000
| New | +$78K |
|
174
BioAtla
BCAB
$27.1M
| $67.5K | 0.01% |
+170,506
| New | +$67.5K |
|
175
Compass Therapeutics
CMPX
$473M
| $65K | 0.01% |
+25,000
| New | +$65K |
|